NASDAQ:HRTX Heron Therapeutics (HRTX) Stock Price, News & Analysis → Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning (From American Hartford Gold Group) (Ad) Free HRTX Stock Alerts $2.53 +0.08 (+3.27%) (As of 09:34 AM ET) Add Compare Share Share Today's Range$2.45▼$2.5550-Day Range$2.36▼$3.0652-Week Range$0.50▼$3.22Volume84,941 shsAverage Volume2.75 million shsMarket Capitalization$380.33 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Heron Therapeutics alerts: Email Address Heron Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside124.5% Upside$5.50 Price TargetShort InterestBearish16.92% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.71Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.24) to ($0.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.01 out of 5 starsMedical Sector181st out of 915 stocksBiotechnology Industry3rd out of 22 stocks 3.5 Analyst's Opinion Consensus RatingHeron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.92% of the outstanding shares of Heron Therapeutics have been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Heron Therapeutics has recently decreased by 0.47%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHeron Therapeutics has received a 61.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Antiemetics and antinauseants (A04)", "Bupivacaine", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Heron Therapeutics is -1.96. Previous Next 2.6 News and Social Media Coverage News SentimentHeron Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Heron Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 13 people have searched for HRTX on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -58% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($0.24) to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Heron Therapeutics Stock (NASDAQ:HRTX)Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Read More HRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRTX Stock News HeadlinesApril 26, 2024 | americanbankingnews.comHeron Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.09) Per Share, Capital One Financial Forecasts (NASDAQ:HRTX)April 25, 2024 | finance.yahoo.comHeron Therapeutics, Inc.'s (NASDAQ:HRTX) Profit OutlookApril 29, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.April 24, 2024 | prnewswire.comHeron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024April 24, 2024 | americanbankingnews.comHeron Therapeutics (NASDAQ:HRTX) Coverage Initiated by Analysts at Capital One FinancialApril 23, 2024 | msn.comCapital One Initiates Coverage of Heron Therapeutics (HRTX) with Overweight RecommendationApril 16, 2024 | seekingalpha.comHeron Therapeutics: Zynrelef Potentially Eases Shareholder PainApril 12, 2024 | nasdaq.comCommit To Buy Heron Therapeutics At $2, Earn 22.4% Annualized Using OptionsApril 29, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.April 11, 2024 | prnewswire.comHeron Therapeutics to Host Investor Day on May 15, 2024 in New York CityMarch 28, 2024 | prnewswire.comHeron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 16, 2024 | ca.finance.yahoo.comHRTX Apr 2024 1.500 callMarch 14, 2024 | finance.yahoo.comHeron Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 14, 2024 | marketwatch.comHeron Therapeutics Soars After 4Q Earnings BeatMarch 13, 2024 | theglobeandmail.comBiotech Finds Mid-Week Success Following Q4 Earnings ReleaseMarch 13, 2024 | markets.businessinsider.comWhy Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?March 13, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | finance.yahoo.comQ4 2023 Heron Therapeutics Inc Earnings CallMarch 12, 2024 | finance.yahoo.comHeron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate UpdatesMarch 12, 2024 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023March 11, 2024 | msn.comHeron Therapeutics Q4 2023 Earnings PreviewMarch 11, 2024 | markets.businessinsider.comWhat Wall Street expects from Heron Therapeutics's earningsMarch 11, 2024 | benzinga.comPreview: Heron Therapeutics's EarningsFebruary 28, 2024 | finance.yahoo.comHeron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024February 28, 2024 | prnewswire.comHeron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024February 24, 2024 | msn.comHeron Therapeutics (HRTX) Price Target Increased by 18.52% to 6.80February 22, 2024 | benzinga.comHeron Therapeutics Stock (NASDAQ:HRTX), Short Interest ReportSee More Headlines Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/29/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:HRTX CUSIPN/A CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees126Year Founded1983Price Target and Rating Average Stock Price Target$5.50 High Stock Price Target$6.00 Low Stock Price Target$5.00 Potential Upside/Downside+124.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,560,000.00 Net Margins-87.02% Pretax Margin-87.02% Return on EquityN/A Return on Assets-50.61% Debt Debt-to-Equity RatioN/A Current Ratio2.37 Quick Ratio1.84 Sales & Book Value Annual Sales$127.04 million Price / Sales2.90 Cash FlowN/A Price / Cash FlowN/A Book Value($0.23) per share Price / Book-10.65Miscellaneous Outstanding Shares150,329,000Free Float140,708,000Market Cap$368.31 million OptionableOptionable Beta1.68 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Craig Alexander Collard (Age 58)CEO & Director Ms. Ira Duarte (Age 55)Executive VP & CFO Mr. Ryan CraigVice President of MarketingMr. Sean T. Ristine (Age 54)Senior Vice President of Human Resources Mr. Robert Sullivan (Age 46)Senior VP of Oncology Care Franchise & Commercial Operations Dr. William P. Forbes Pharm. D. (Age 62)Pharm.D., Executive VP & Chief Development Officer Jeff CohnExecutive Director, Assistant General Counsel & Assistant SecretaryMore ExecutivesKey CompetitorsMersana TherapeuticsNASDAQ:MRSNOrganogenesisNASDAQ:ORGOBiomea FusionNASDAQ:BMEAEsperion TherapeuticsNASDAQ:ESPRCorbus PharmaceuticalsNASDAQ:CRBPView All CompetitorsInsiders & InstitutionsDiversified Trust CoBought 23,966 shares on 4/18/2024Ownership: 0.016%Congress Park Capital LLCSold 153,865 shares on 4/16/2024Ownership: 1.094%Los Angeles Capital Management LLCSold 21,113 shares on 4/5/2024Ownership: 0.328%Orchard Capital Management LLCBought 100,603 shares on 2/15/2024Ownership: 1.495%D.A. Davidson & CO.Sold 10,500 shares on 2/9/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions HRTX Stock Analysis - Frequently Asked Questions Should I buy or sell Heron Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HRTX shares. View HRTX analyst ratings or view top-rated stocks. What is Heron Therapeutics' stock price target for 2024? 3 brokers have issued 12 month price targets for Heron Therapeutics' shares. Their HRTX share price targets range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 124.5% from the stock's current price. View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts. How have HRTX shares performed in 2024? Heron Therapeutics' stock was trading at $1.70 on January 1st, 2024. Since then, HRTX shares have increased by 44.1% and is now trading at $2.45. View the best growth stocks for 2024 here. When is Heron Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our HRTX earnings forecast. How can I listen to Heron Therapeutics' earnings call? Heron Therapeutics will be holding an earnings conference call on Tuesday, May 7th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings data on Tuesday, March, 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.08. The biotechnology company earned $34.23 million during the quarter, compared to analyst estimates of $30.98 million. What ETF holds Heron Therapeutics' stock? Jacob Forward ETF holds 50,351 shares of HRTX stock, representing 4.61% of its portfolio. What guidance has Heron Therapeutics issued on next quarter's earnings? Heron Therapeutics issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $138.0 million-$158.0 million, compared to the consensus revenue estimate of $139.1 million. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN). Who are Heron Therapeutics' major shareholders? Heron Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Congress Park Capital LLC (1.09%), Los Angeles Capital Management LLC (0.33%) and Diversified Trust Co (0.02%). Insiders that own company stock include Adam Morgan, Craig A Collard, Ira Duarte, Kimberly Manhard, Waage Christian and William P Forbes. View institutional ownership trends. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Heron Therapeutics have any subsidiaries? The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..Read More This page (NASDAQ:HRTX) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsBiden out June 13; Kamala won’t replace him?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
